<i>S</i>-Alkylated quinazolin-4(3<i>H</i>)-ones as dual EGFR/VEGFR-2 kinases inhibitors: design, synthesis, anticancer evaluation and docking study-Reference-Cited by-同舟云学术

S-Alkylated quinazolin-4(3H)-ones as dual EGFR/VEGFR-2 kinases inhibitors: design, synthesis, anticancer evaluation and docking study

Published:2024 Issue:36 Volume:14 Page:26325-26339
ISSN:2046-2069
Container-title:RSC Advances
language:en
Short-container-title:RSC Adv.

Author:

Tawfik Samar S.¹^ORCID,Hamdi Abdelrahman¹^ORCID,Ali Ahmed R.²^ORCID,Elgazar Abdullah A.³^ORCID,El-Shafey Hamed W.¹,El-Azab Adel S.⁴^ORCID,Bakheit Ahmed H.⁴,Hefnawy Mohamed M.⁴,Ghabbour Hazem A.⁵^ORCID,Abdel-Aziz Alaa A.-M.⁴^ORCID

Affiliation:

1. Department of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, Mansoura University, Mansoura 35516, Egypt

2. Department of Medicinal Chemistry, Faculty of Pharmacy, Mansoura University, Mansoura 35516, Egypt

3. Department of Pharmacognosy, Faculty of Pharmacy, Kafrelsheikh University, Kafr El Sheikh, Egypt

4. Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, P. O. Box 2457, Riyadh 11451, Saudi Arabia

5. School of Health and Biomedical Sciences, RMIT University, Melbourne 3083, Australia

Abstract

Novel quinazolin-4(3H)-ones 4–27 were synthesized. Compounds 4, 11, and 20 showed potential anti-tumour activities. 4, 11, and 20 blocked EGFR/VEGFR-2 and triggered apoptosis. Compound 4 showed the most potent activity against EGFR/VEGFR-2.

Funder

King Saud University

Publisher

Royal Society of Chemistry (RSC)

Link

http://pubs.rsc.org/en/content/articlepdf/2024/RA/D4RA04828H

Reference83 articles.

1. ICONIC: An international task force supporting collaboration in nutrition and cancer globally

2. Synthesis and In vivo Antifibrotic Activity of Novel Leflunomide Analogues

3. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries

4. Acquired chemotherapy resistance in ovarian cancer

5. Combination of ligand and structure based virtual screening approaches for the discovery of potential PARP1 inhibitors